SCHEMBL28022120

SCHEMBL28022120

CC(=O)Nc1ccc(S(=O)(=O)c2nc(Nc3cc(C)n[nH]3)c(C)c(-c3ccccc3)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 6/20 0.39
▸ KMT2A Q03164 6/20 0.39
▸ MAPT P10636 5/20 0.39
▸ KDM4E B2RXH2 3/20 0.39
▸ PKM P14618 1/20 0.39
▸ HPGD P15428 3/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ RXFP1 Q9HBX9 2/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ TTR P02766 1/20 0.38
▸ TNIK Q9UKE5 1/20 0.38
▸ POLB P06746 3/20 0.38
▸ GFER P55789 2/20 0.38
▸ GAA P10253 2/20 0.38
▸ TSHR P16473 1/20 0.38
▸ LMNA P02545 2/20 0.37
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ MMP1 P03956 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28562238 0.89 MAPT (0.38) MEN1KMT2AMAPTKDM4EPKM
SCHEMBL28557357 0.83 AURKB (0.49) MEN1KMT2AMAPTKDM4EPKM
SCHEMBL2204132 0.81 AURKB (0.54) MEN1KMT2AMAPTKDM4EHPGD
SCHEMBL28022063 0.78 SMN1; SMN2 (0.42) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL28556178 0.76 AURKA (0.39) MEN1KMT2AMAPTKDM4EPKM
SCHEMBL28022078 0.76 PKM (0.44) MEN1KMT2AMAPTKDM4EPKM
SCHEMBL28022048 0.75 AURKA (0.46) MAPTKDM4EPKMALDH1A1NPSR1
SCHEMBL28548957 0.73 ADORA1 (0.44) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL28021591 0.73 AURKB (0.51) MEN1KMT2AMAPTKDM4EHPGD
SCHEMBL28549342 0.73 ACHE (0.48) MEN1KMT2AMAPTKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112755193-A Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof 德玛医药 2021-05-07 — — CN disclosed
CN-104797267-A Method of treating tyrosine kinase inhibitor-resistant malignancies in patients with genetic polymorphism or AHI1 dysregulation or mutation using dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof DEL MAR PHARMACEUTICALS 2015-07-22 — — CN disclosed
Send feedback